Update on neuropathies associated with monoclonal gammopathy of undetermined significance (2008-2010)

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Studies on paraproteinemic neuropathies have appeared in the last 2 years improving the diagnosis of these neuropathies, clarifying their pathogenesis, and informing practice by randomized clinical trial publications. Two recent randomized controlled trials with rituximab failed to provide evidence of efficacy in primary outcome measures, despite the fact that anti-myelin- associated glycoprotein (MAG) antibodies were reduced in most treated patients. This discrepancy, besides inducing the search for more effective therapy for this neuropathy, indicates that some aspects on the pathogenesis of this neuropathy probably need further clarification.

Original languageEnglish
Pages (from-to)302-306
Number of pages5
JournalJournal of the Peripheral Nervous System
Volume15
Issue number4
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Monoclonal Gammopathy of Undetermined Significance
Randomized Controlled Trials
Myelin-Associated Glycoprotein
Publications
Outcome Assessment (Health Care)
Antibodies
Therapeutics
Rituximab

Keywords

  • antibodies
  • ganglioside complexes
  • GQ1b
  • IgM
  • MAG
  • monoclonal gammopathy
  • neuropathy
  • rituximab
  • sulfatide

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

@article{332f311a8c3e4296ac7632324f5d388d,
title = "Update on neuropathies associated with monoclonal gammopathy of undetermined significance (2008-2010)",
abstract = "Studies on paraproteinemic neuropathies have appeared in the last 2 years improving the diagnosis of these neuropathies, clarifying their pathogenesis, and informing practice by randomized clinical trial publications. Two recent randomized controlled trials with rituximab failed to provide evidence of efficacy in primary outcome measures, despite the fact that anti-myelin- associated glycoprotein (MAG) antibodies were reduced in most treated patients. This discrepancy, besides inducing the search for more effective therapy for this neuropathy, indicates that some aspects on the pathogenesis of this neuropathy probably need further clarification.",
keywords = "antibodies, ganglioside complexes, GQ1b, IgM, MAG, monoclonal gammopathy, neuropathy, rituximab, sulfatide",
author = "Eduardo Nobile-Orazio",
year = "2010",
month = "12",
doi = "10.1111/j.1529-8027.2010.00283.x",
language = "English",
volume = "15",
pages = "302--306",
journal = "Journal of the Peripheral Nervous System",
issn = "1085-9489",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Update on neuropathies associated with monoclonal gammopathy of undetermined significance (2008-2010)

AU - Nobile-Orazio, Eduardo

PY - 2010/12

Y1 - 2010/12

N2 - Studies on paraproteinemic neuropathies have appeared in the last 2 years improving the diagnosis of these neuropathies, clarifying their pathogenesis, and informing practice by randomized clinical trial publications. Two recent randomized controlled trials with rituximab failed to provide evidence of efficacy in primary outcome measures, despite the fact that anti-myelin- associated glycoprotein (MAG) antibodies were reduced in most treated patients. This discrepancy, besides inducing the search for more effective therapy for this neuropathy, indicates that some aspects on the pathogenesis of this neuropathy probably need further clarification.

AB - Studies on paraproteinemic neuropathies have appeared in the last 2 years improving the diagnosis of these neuropathies, clarifying their pathogenesis, and informing practice by randomized clinical trial publications. Two recent randomized controlled trials with rituximab failed to provide evidence of efficacy in primary outcome measures, despite the fact that anti-myelin- associated glycoprotein (MAG) antibodies were reduced in most treated patients. This discrepancy, besides inducing the search for more effective therapy for this neuropathy, indicates that some aspects on the pathogenesis of this neuropathy probably need further clarification.

KW - antibodies

KW - ganglioside complexes

KW - GQ1b

KW - IgM

KW - MAG

KW - monoclonal gammopathy

KW - neuropathy

KW - rituximab

KW - sulfatide

UR - http://www.scopus.com/inward/record.url?scp=78650805520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650805520&partnerID=8YFLogxK

U2 - 10.1111/j.1529-8027.2010.00283.x

DO - 10.1111/j.1529-8027.2010.00283.x

M3 - Article

C2 - 21199101

AN - SCOPUS:78650805520

VL - 15

SP - 302

EP - 306

JO - Journal of the Peripheral Nervous System

JF - Journal of the Peripheral Nervous System

SN - 1085-9489

IS - 4

ER -